CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

N-acetylcysteineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.06
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease

The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease

NCT04419025 COVID Sars-CoV2 SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere Drug: N-acetylcysteine
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Decrease in dyspnea measured by respiratory rate (RR)

Measure: Decrease in Respiratory Rate

Time: First hour after first dose of NAC

Description: Hospital LOS for admitted patients

Measure: Hospital length of stay (LOS)

Time: Through study completion, average 9 months

Description: Whether a patient needed mechanical ventilation (intubation)

Measure: Need for mechanical ventilation

Time: Through study completion, average 9 months

Description: If intubated, how long needing mechanical ventilation

Measure: Length of time intubated

Time: Through study completion, average 9 months

Description: Outpatients on NAC needing admission to the hospital

Measure: Need for hospitalization

Time: Through study completion, average 9 months

Description: Whether outpatients continued to recover as outpatients; whether admitted patients were managed on medical floors or level of care increased to ICU level of care; whether patients expired

Measure: Recovery disposition

Time: Through study completion, average 9 months

No related HPO nodes (Using clinical trials)